From “It’s Great to Be a Woman” to a 40 Billion Market Value: The Transfer of Power and Hidden Concerns in Zhu Baoguo’s Retirement
Hello everyone, I’m your financial observer. Today, we’re talking about an entrepreneur who etched the slogan “It’s Great to Be a Woman” into the memories of several generations—Zhu Baoguo.
On the evening of September 11th, he announced his retirement from the positions of chairman of two listed companies, Health Yuan and Livzon Group. Although he has stepped down, he remains the de facto owner of both companies, with a family fortune of 59 billion yuan.
This is not just about an entrepreneur’s retirement; it’s also a microcosm of the changes in China’s business landscape: from starting with aggressive advertising to acquire established pharmaceutical companies through capital operations, to now facing the dual challenges of price cuts from centralized procurement and the need for innovative transformation.
Let’s break down this news into five key points to understand the logic behind it.
---
1. The Journey to Success: 90,000 Yuan for a Formula, 5 Million Yuan for Advertising, and a Brainwashing Campaign
Zhu Baoguo’s story is a classic example of seizing the right opportunities in the right moment.
Core Logic: Information Gap +饱和 Advertising
- Low-cost Entry, High Premium Sale: In 1993, Zhu Baoguo bought a formula for treating chloasma from a hospital in Xinxiang, Henan, for 90,000 yuan. At the time, it might have seemed like an ordinary remedy, but he saw a market niche: the health supplement market was focused on “strengthening the body” or “child nutrition,” with very few products targeting adult women specifically for beauty and wellness.
- Daring Marketing: To promote the product, he took a risky move by mortgaging his factory and investing 5 million yuan in advertising. In 1995, he spent another 10 million yuan on prime TV airtime. Without the internet, television was the main channel for reaching consumers.
- Comprehensive Coverage: In addition to television, he covered the Shenzhen International Trade Center and Shennan Avenue with billboards and even advertised on rural walls. With endorsements from celebrities like Mao Amin and Lin Zhiling, the slogan “It’s Great to Be a Woman” became deeply ingrained in the minds of women.
Result: A single counter in a Guangzhou department store sold 300,000 units a day, leaving sales staff in awe. The “Tai Tai Oral Liquid” became a phenomenon, and Zhu Baoguo built a solid foundation for his business.
Plain Language: It’s like modern influencer marketing. Zhu Baoguo was the “top influencer” of his era, with a differentiated product (focusing on women’s beauty) and aggressive marketing strategies. In an era of limited information and nascent brand awareness, the one with the loudest voice and the widest reach became the leader.
---
2. The Pain of Transformation: The Limitations of Health Supplements, Moving from “Water Selling” to “Pharmaceutical Development”
Some might wonder why Zhu Baoguo would abandon a profitable health supplement to venture into complex pharmaceutical research and development.
Core Logic: Lifecycle Management + Market Shift
- End of the Growth Period: Entering the 21st century, the growth of Tai Tai Oral Liquid slowed down (only 3.7% in 2003). Competitors like “Duo Er” emerged, turning the market from a blue ocean into a red ocean.
- Proactive Change: Zhu Baoguo was a proactive entrepreneur. He began investing in pharmaceuticals early on, acquiring Haibin Pharmaceutical in 1997, listing Tai Tai Pharmaceutical in 2001, and renaming the company Health Yuan in 2003, shedding the health supplement image.
Plain Language: Selling health supplements is like selling fast-moving consumer goods; the barrier is low, but it’s easy for competitors to imitate, and there are regulatory risks. Pharmaceutical development, especially for chemical and active pharmaceutical ingredients, is more challenging but offers long-term stability.
---
3. The Capital Game: The Dramatic Acquisition of Livzon Group
If pharmaceutical development was Zhu Baoguo’s “inner strength,” then the acquisition of Livzon Group was the highlight of his business career.
Core Logic: Capital Operations + Control Battle
- Repeated Attempts: Zhu Baoguo wanted to buy Livzon Group since 1996 but failed.
- A Swift Move: In 2002, Livzon’s founder, Xu Xiaoxian, called him and offered to sell his shares. Zhu Baoguo acted quickly, signing the agreement the next day.
- A Complex Battle: Signing the agreement didn’t guarantee victory. Another competitor, Guo Jiaxue from Dongsheng Group, also joined the competition. The two sides engaged in a years-long battle for control through share acquisitions and voting rights.
- Final Victory: Zhu Baoguo gradually increased his shareholding and eventually became the chairman, taking control of Livzon Group.
Plain Language: It was like a poker game. Zhu Baoguo had the necessary funds but needed the “trump card” (control). He had to negotiate with the founder and compete with other investors. This victory elevated him from a health supplement entrepreneur to the leader of a large pharmaceutical group, with Livzon becoming a key pillar of his empire.
---
4. Business Expansion: A Dual-Driven Strategy
After acquiring Livzon, Zhu Baoguo continued to expand, creating a unique business structure.
Core Logic: Stable Foundation + New Growth Drivers
- Health Yuan (Core Business):
- Dominant in Active Pharmaceutical Ingredients: Health Yuan is a global player in antibiotic active pharmaceutical ingredients (e.g., 7-ACA, meropenem). This is its stable source of revenue, though less profitable but large in volume.
- Breakthrough in Respiratory Drugs: In 2013, it entered the high-end inhaler market, and its products saw a 22-fold increase in sales within four years. It’s now expanding into innovative drugs, with its first Class 1 innovative drug approved in 2025.
- Livzon Group (Acquired Business):
- Comprehensive Pharmaceutical Production: Livzon covers chemical and traditional Chinese medicine products, with strengths in digestive and assisted reproductive therapies.
- Biopharmaceuticals: Livzon’s monoclonal antibody division has seen its first drug approved in 2021, marking the beginning of a new growth phase.
Plain Language: Zhu Baoguo’s empire is like a combination punch:**
- Active Pharmaceutical Ingredients provide a stable revenue base.
- Livzon Group is the main profit driver.
- Innovative Drugs represent future growth potential.
---
5. Current Challenges: Price Cuts for Old Drugs, Unreached New Drugs, and the New Management’s Challenges
Finally, the practical question: What challenges does the company face with Zhu Baoguo’s retirement?
Core Logic: Transition Period + Policy Pressure
- Performance Decline: In the first half of 2026, Health Yuan and Livzon Group’s revenue and net profit both declined by double digits (16%-20% in revenue, 17%-27% in profit).
- Reason 1: Pressure from Price Cuts: Traditional products are under the impact of medical insurance price cuts and centralized procurement. Sales may increase, but profits are shrinking.
- Reason 2: Unreached New Drugs: Although innovative drugs are growing, they are still not large enough to compensate for the decline in traditional products. It’s like a car with a broken old engine and a new engine that’s just starting to run.
Plain Language: Health Yuan and Livzon are in a transitional phase:
- Traditional businesses are still profitable but face reduced margins due to price cuts.
- New businesses are promising but not yet strong enough to replace the old ones.
Challenges for the New Managers (Post-80s: Lin Nanqi, Liu Daping):
- They’re taking over a company undergoing a major transformation, not a stable one. Their tasks include:
- Accelerating New Drug Commercialization: Making innovative drugs more profitable.
- Optimizing Old Products: Managing costs and competing through differentiation under centralized procurement pressure.
- Strategic Focus: The Zhu Baoguo era was one of bold capital moves; the future requires more refined operations and sustained investment in innovation.
---
In conclusion, Zhu Baoguo’s retirement marks the end of an era. He started with a simple formula and a large advertising budget, used capital to acquire a company, and built a pharmaceutical empire worth 40 billion yuan.
However, he leaves behind a company facing the challenges of price cuts and the need for innovative transformation. For the new managers, the path forward lies in leveraging product and innovation rather than relying on aggressive marketing and acquisitions.
This story is not just about Zhu Baoguo; it’s also a reflection of China’s pharmaceutical industry’s shift from marketing-driven growth to innovation-driven development.